Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia

NCT01097304 | Completed Phase 2 Results

• 7 other identifiers: NCI-2012-00450CDR000066911109-0141-03UAZ08-11-01P50CA095060N01CN35158P30CA023074
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 4

Brief Summary

This pilot phase II trial studies how well ursodiol works in treating patients with Barrett esophagus or cells that look abnormal under a microscope but are not cancer (low-grade dysplasia). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of ursodiol may keep cancer for forming in patients with Barrett esophagus or low-grade dysplasia.

Conditions

Barrett Esophagus; Esophageal Carcinoma

Outcome Measures

Primary Outcomes (1)

• Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining

  8OHdG will be assessed by percentage of positively stained nuclear area. A paired t-test at a one-sided 0.05 significance level will be used to assess change during intervention. The observed results will be reported along with the corresponding confidence intervals.

  Baseline to 6 months

Secondary Outcomes (3)

• Changes in Gastric Bile Acid Composition (Change in Percent of Total Bile Acid Present as Ursodeoxycholic Acid and Its Glycine/Taurine Conjugates) Measured by Liquid Chromatography-tandem Mass Spectrometry, From Baseline to Post-intervention

  Baseline and 6 months

• Changes in Gastric Bile Acid Composition (Change in Percent of Total Bile Acid Present as Deoxycholic Acid and Its Glycine/Taurine Conjugates) Measured by Liquid Chromatography-tandem Mass Spectrometry, From Baseline to Post-intervention

  Baseline and 6 months

• Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections

  Baseline and 6 months

Study Arms (1)

Treatment (ursodiol)

EXPERIMENTAL

Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.

Drug: Ursodiol; Other: Laboratory Biomarker Analysis

Interventions

Ursodiol DRUG

Given PO

Also known as: Actigall, Deursil, UDCA, URSO

Treatment (ursodiol)

Laboratory Biomarker Analysis OTHER

Correlative studies

Treatment (ursodiol)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of Barrett's esophagus with histologically-confirmed intestinal metaplasia anywhere in the tubular esophagus either with \>= 2 cm of involvement or with a minimum circumferential Barrett's esophagus (BE) length of 1 cm
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Leukocytes \>= 3,000/uL
• Absolute neutrophil count \>= 1,500/uL
• Platelets \>= 100,000/uL
• Total bilirubin =\< 2.0 mg/dL
• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 2 X institutional upper limit of normal (ULN)
• Creatinine =\< 1X ULN
• Women of child-bearing potential (i.e., not surgically sterile or less than one year since last menstrual period) agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; women of childbearing potential must have a negative urine pregnancy test within 14 days prior to study agent administration; male subjects must agree to use adequate contraception (barrier method, abstinence, subject has had vasectomy or partner is using effective birth control or is postmenopausal)
• Ability to understand and the willingness to sign a written informed consent document
• Agree to refrain from any non-steroidal anti-inflammatory drug (NSAID) with the exception of low-dose aspirin (81 mg once daily \[QD\]) during the entire study period
• Agree not to take aluminum-containing antacids and anion exchange resins such as cholestyramine, colestimide or colestipol within 2 hours of taking UDCA

You may not qualify if:

• Barrett's esophagus with high grade dysplasia or carcinoma at enrollment
• Medical conditions which would make completing endoscopies or completing the trial difficult including but not limited to previous transient ischemic attacks or cerebral vascular disease, severe respiratory disease, severe ischemic heart disease or myocardial infarction in the previous 6 months, inflammatory bowel disease
• Participants may not be receiving any other investigational agents within 1 month of study enrollment
• Have used NSAID for more than 5 days per month within 1 month of enrollment except low dose aspirin (81 mg QD)
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to UDCA
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued during treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
• Have had major upper gastrointestinal (GI) surgeries within 6 months of enrollment including, but not limited to, fundoplication, bariatric surgery, cholecystectomy
• Erosive esophagitis detected at the baseline endoscopy
• Participants who need concurrent chemotherapy, radiotherapy, or cancer-related hormonal or immunotherapy during the time of study
• Participants who have had chemotherapy, radiotherapy, or cancer-related hormonal or immunotherapy within 18 months of the baseline visit
• Current or planned use of anticoagulant drugs including, but not limited to, warfarin, heparin, low molecular weight heparin, Plavix, or Aggrenox
• Use of cyclosporine during the time of study

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (4)

Southern Arizona Veterans Affairs Health Center

Tucson, Arizona, 85723, United States

Location

Arizona Cancer Center-North Campus

Tucson, Arizona, 85724-5024, United States

Location

University of Arizona Health Sciences Center

Tucson, Arizona, 85724, United States

Location

University of North Carolina

Chapel Hill, North Carolina, 27599, United States

Location

MeSH Terms

Conditions

Barrett Esophagus; Esophageal Neoplasms

Interventions

Ursodeoxycholic Acid

Condition Hierarchy (Ancestors)

Precancerous Conditions; Neoplasms; Esophageal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Head and Neck Neoplasms

Intervention Hierarchy (Ancestors)

Deoxycholic Acid; Cholic Acids; Bile Acids and Salts; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Cholanes

Results Point of Contact

• Title: Dr. Sherry Chow
• Organization: University of Arizona

schow@azcc.arizona.edu

520-626-3358

Study Officials

• Bhaskar Banerjee

  University of Arizona Health Sciences Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 31, 2010
• First Posted: April 1, 2010
• Study Start: April 1, 2010
• Primary Completion: April 1, 2014
• Study Completion: July 1, 2014
• Last Updated: December 19, 2017
• Results First Posted: May 15, 2015

Record last verified: 2017-11

Locations

US (4)